S&P 500 7,431.46 +0.50% NASDAQ 25,888.84 +0.31% DOW 51,202.26 +0.70% R2K 2,943.99 +0.79% VIX 17.68 -9.05% US 10Y 4.49 +0.54% DXY 99.75 -0.11% GOLD 4,215.00 +3.05% CRUDE 84.88 -3.23% BITCOIN 63,637.33 +0.15%
Next Bullish Trade
ZTS Zoetis Inc. NYQ
$79.57 -1.83 (-2.25%)
Pullback · -0.96σ Grade C
+ Compare Set alert Open in Sniper

Price chart

Overlay: Click earnings ▲ markers for day-move details

Loading 1Y daily…

Financial overlay · last 12 quarters

QuarterRevenue Net incomeOp income FCFNet margin Op margin
2026-03-31 $2.3B $0.6B $0.8B $0.3B 26.6% 36.3%
2025-12-31 $2.4B $0.6B $0.8B $0.7B 25.3% 34.6%
2025-09-30 $2.4B $0.7B $0.9B $0.8B 30.0% 39.0%
2025-06-30 $2.5B $0.7B $1.0B $0.4B 29.2% 40.2%
2025-03-31 $2.2B $0.6B $0.8B $0.3B 27.4% 36.9%
2024-12-31 $nanB $nanB $nanB $nanB nan% nan%
2024-09-30 $nanB $nanB $nanB $nanB nan% nan%

Earnings replay · last 20 reports

DateEPS actual EPS estSurprise
2026-05-07 1.42 1.54 -7.6%
2026-02-12 1.48 1.40 +5.5%
2025-11-04 1.70 1.62 +4.8%
2025-08-05 1.61 1.52 +5.8%
2025-05-06 1.48 1.40 +5.8%
2025-02-13 1.40 1.36 +2.8%
2024-11-04 1.58 1.46 +8.0%
2024-08-06 1.56 1.48 +5.3%
2024-05-02 1.31 1.27 +3.5%
2024-02-13 1.24 1.32 -5.9%
2023-11-02 1.36 1.36 +0.4%
2023-08-08 1.41 1.31 +8.0%
2023-05-04 1.31 1.25 +4.5%
2023-02-14 1.15 1.15 +0.3%
2022-11-03 1.21 1.24 -2.1%
2022-08-04 1.20 1.22 -1.6%
2022-05-05 1.32 1.22 +8.0%
2022-02-15 1.00 0.96 +3.8%
2021-11-04 1.25 1.11 +12.5%
2021-08-05 1.19 1.09 +9.3%

Earnings markers are overlaid on the price chart above. Transcript summaries require PERPLEXITY_API_KEY (deferred to a follow-up).

Peer comparison · Healthcare

Ticker ⇅ Mkt cap ⇅ P/E ⇅ Fwd P/E ⇅ P/S ⇅ EV/EBITDA ⇅ P/B ⇅ Gross M ⇅ Rev gr ⇅ EPS gr ⇅ FCF yld ⇅
ZTS ★ $33B 13.0 10.7 3.5 10.0 10.2 71.8% 2.9% 6.0% 5.34%
LLY $1,010B 40.3 25.5 14.0 28.9 32.4 82.8% 55.5% 169.9% 0.91%
UNH $371B 30.8 19.5 0.8 19.8 3.8 18.8% 2.0% 0.7% 4.77%
JNJ $580B 27.9 18.9 6.0 17.9 7.1 68.0% 9.9% -52.9% 2.16%
MRK $294B 33.5 12.4 4.5 11.4 6.4 76.7% 4.9% — 4.78%
ABBV $402B 111.1 14.0 6.4 15.6 -60.5 72.0% 12.4% -46.2% 5.17%
PFE $149B 20.0 9.3 2.4 7.9 1.7 74.8% 5.4% -10.1% 8.29%
TMO $174B 25.8 17.2 3.9 19.0 3.3 40.9% 6.2% 11.3% 3.17%

Auto-seeded from sector. Click any ticker to switch.

Ownership

Top institutional holders

Top-10 concentration: 40.05%

HolderShares% out
Blackrock Inc. 35,584,312 8.49%
Vanguard Capital Management LLC 26,072,846 6.22%
Vanguard Portfolio Management LLC 23,967,400 5.72%
State Street Corporation 19,324,401 4.61%
State Farm Mutual Automobile Insuran 15,892,903 3.79%
Morgan Stanley 14,145,735 3.37%
Geode Capital Management, LLC 11,349,248 2.71%
Wellington Management Group, LLP 10,150,096 2.42%
Nordea Investment Management AB 5,865,111 1.40%
Northern Trust Corporation 5,546,057 1.32%

Insider activity · 90d

5 buys / 0 sells · ratio 5.0 · Finnhub

  • MCCALLISTER MICHAEL B G 0
  • Stetter Mark M 0
  • Stetter Mark M 1,572
  • PARENT LOUISE M M 0
  • PARENT LOUISE M M 0
  • PARENT LOUISE M M 28,394
  • PARENT LOUISE M M 18,208
  • Bisaro Paul BUY 27,862 @ $75.88
  • DAMELIO FRANK A BUY 21,458 @ $75.39
  • MCCALLISTER MICHAEL B BUY 24,524 @ $77.76

Analyst estimates

Finnhub
Low
$90.0
Mean
$124.58824
High
$160.0
Analysts
17
Recommendation distribution · period 2026-06-01
6
8
10
Revision trend (2026-03-01 → 2026-06-01): net 16 → 14 -2 (net = strong_buy+buy − sell−strong_sell)

SEC filings

FormFiled DescriptionAction
4 2026-06-11 FORM 4 view ·
4 2026-05-26 FORM 4 view ·
8-K 2026-05-22 8-K view ·
4 2026-05-21 FORM 4 view ·
8-K 2026-05-20 8-K view ·
4 2026-05-13 FORM 4 view ·
4 2026-05-13 FORM 4 view ·
4 2026-05-12 FORM 4 view ·
10-Q 2026-05-07 10-Q view ·
8-K 2026-05-07 8-K view ·
4 2026-05-01 FORM 4 view ·
4 2026-04-13 FORM 4 view ·
4 2026-04-13 FORM 4 view ·
4 2026-04-13 FORM 4 view ·
4 2026-04-13 FORM 4 view ·
4 2026-04-13 FORM 4 view ·
4 2026-04-13 FORM 4 view ·
4 2026-04-13 FORM 4 view ·
4 2026-04-13 FORM 4 view ·
DEF 14A 2026-04-08 DEF 14A view ·
4 2026-04-01 FORM 4 view ·
4 2026-03-31 FORM 4 view ·
4 2026-03-31 FORM 4 view ·
4 2026-03-31 FORM 4 view ·
4 2026-03-31 FORM 4 view ·
4 2026-03-31 FORM 4 view ·
4 2026-03-31 FORM 4 view ·
4 2026-03-31 FORM 4 view ·
4 2026-03-31 FORM 4 view ·
4 2026-03-20 FORM 4 view ·
4 2026-03-10 FORM 4 view ·
4 2026-02-23 FORM 4 view ·
4 2026-02-23 FORM 4 view ·
4 2026-02-23 FORM 4 view ·
4 2026-02-23 FORM 4 view ·
4 2026-02-23 FORM 4 view ·
4 2026-02-23 FORM 4 view ·
4 2026-02-23 FORM 4 view ·
4 2026-02-23 FORM 4 view ·
4 2026-02-23 FORM 4 view ·
4 2026-02-23 FORM 4 view ·
4 2026-02-23 FORM 4 view ·
4 2026-02-23 FORM 4 view ·
4 2026-02-23 FORM 4 view ·
4 2026-02-23 FORM 4 view ·
4 2026-02-23 FORM 4 view ·
4 2026-02-23 FORM 4 view ·
4 2026-02-23 FORM 4 view ·
4 2026-02-23 FORM 4 view ·
4 2026-02-23 FORM 4 view ·
4 2026-02-23 FORM 4 view ·
4 2026-02-19 FORM 4 view ·
4 2026-02-19 FORM 4 view ·
4 2026-02-19 FORM 4 view ·
4 2026-02-19 FORM 4 view ·
4 2026-02-19 FORM 4 view ·
4 2026-02-19 FORM 4 view ·
4 2026-02-19 FORM 4 view ·
4 2026-02-19 FORM 4 view ·
4 2026-02-19 FORM 4 view ·

About

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zo…